In fact, several avenues of IL-10 inhibition (including anti-IL-10 monoclonal antibody therapy and small molecule inhibitors of both JAK2 and NFKB) are being explored as a novel therapeutic approach in DLBCL (Béguelin et al., 2015). Here, JAK2 is linked to diffuse large B-cell lymphoma.